Ces radiol. 2019, 73(2):113-117 | DOI: 10.55095/CesRadiol2019/017

18F-fluorocholine PET/CT restaging imaging in prostate cancer patients with biochemical failure - preliminary reportOriginal article

Eva Krčálová1,4, Martin Slanina2, Dagmar Kalousová2, Zuzana Poulová2, Jan Jansa3, Jiří Doležal1
1 Oddělení nukleární medicíny, Lékařská fakulta v Hradci Králové a Fakultní nemocnice, Hradec Králové
2 Radiologická klinika, Lékařská fakulta v Hradci Králové a Fakultní nemocnice, Hradec Králové
3 Klinika onkologie a radioterapie, Lékařská fakulta v Hradci Králové a Fakultní nemocnice, Hradec Králové
4 Katedra interních oborů, Lékařská fakulta v Hradci Králové

Aim: To evaluate preliminary experience with 18F-fluorocholine PET/CT (FCh PET/CT) restaging imaging in prostate cancer patients with biochemical failure and stress the problems with prostate cancer recurrence detection in patients with low prostate specific antigen (PSA) levels.

Methods: FCh PET/CT was performed for prostate cancer recurrence detection in 24 patients during 16 months. Of them, 14 patients with known clinical outcome were further retrospectively evaluated. We evaluated FCh PET/CT diagnostic performance in relation to PSA levels and PSA kinetics, Gleason score and initial staging.

Results: Median of their PSA levels was 1.76 ng/ml, range: 0.44-2.88. Prostate cancer recurrence was detected in only 6 patients out of 14 using FCh PET/CT, sensitivity reached 43%. FCh PET/CT positive patients had clearly shorter PSA doubling time (median 4.15 versus 10.2 in FCh PET/CT negative ones) and slightly higher Gleason score.

Conclusions: Although we achieved low FCh PET/CT sensitivity in patients with biochemical failure with low PSA levels, our data suggest that FCh PET/CT could be useful in those with still low PSA levels, but short PSA doubling time. PSA doubling time seems to be helpful in selecting (still) low level PSA patients for FCh PET/CT.

Keywords: 18F-fluorocholine, PET/CT, prostate cancer, prostate-specific antigen
Grants and funding:

Práce byla podpořena granty: MZ ČR - RVO (FNHK, 00179906).

Accepted: March 1, 2019; Published: June 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krčálová E, Slanina M, Kalousová D, Poulová Z, Jansa J, Doležal J. 18F-fluorocholine PET/CT restaging imaging in prostate cancer patients with biochemical failure - preliminary report. Ces radiol. 2019;73(2):113-117. doi: 10.55095/CesRadiol2019/017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita 2005 [cit. 2019-3-23]. Dostupný z: http://www.svod.cz. Verze 7.0 [2007].
    2. Dvořák J. Radioterapie karcinomu prostaty. Onkologie 2014; 8(1): 19-22.
    3. Casciato DA, et al. Manual of Clinical Oncology. 7th edition. Philadelphia: Lippincott Williams &Wilkins a Wolters Kluwer bussiness 2012; 381-391.
    4. Klementová Y. Radioterapie karcinomu prostaty - nežádoucí účinky léčby. Urologie pro Praxi 2011; 12(1): 59-60.
    5. Jansa J, Petera J. Hormonální léčba karcinomu prostaty. Urologie pro Praxi 2009; 10(6): 336-338.
    6. Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 2006; 33(12): 1387-1398. Go to original source... Go to PubMed...
    7. Gerbaudo VH, et al. A case - Based approach to PET/CT in onkology, 1st edition. New York: Cambridge University Press 2012. Go to original source...
    8. Ferda J, Kastner J, Ferdová E, et al. Zobrazení karcinomu prostaty na molekulární úrovni - naše zkušenosti. Ces Radiol 2012; 66(3): 289-295.
    9. Doležal J, Kalousová D, Krčálová E, Pokorný K, Vondráčková K. Detekce diseminace maligního schwanomu nervus facialis pomocí hybridního 18F-FDG PET/CT. Ces Radiol 2017; 71(1): 65-69. Go to original source...
    10. Ptáčník V, Kubinyi J. PET/CT vyšetření u pacientů s karcinomem prostaty. Olomouc: Solen 2016; 17(1): 7-10. Go to original source...
    11. Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med 2016; 57(Suppl 3): 55S-60S. Go to original source... Go to PubMed...
    12. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer and Prostatic Diseases 2012; 15(1): 45-55. Go to original source... Go to PubMed...
    13. Ferdová E, Ferda J, Baxa J, Hora M, Hes O, Fínek J. PET/CT S 18F-Fluorocholinem u karcinomu prostaty, dvouleté zkušenosti. Ces Radiol 2014; 68(1): 22-29.
    14. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006; 47(2): 262-269.
    15. Adam J, Demlová R, Řehák Z. Pokroky ve vývoji PET radiofarmak pro pacienty v České republice. Klin Onkol 2016; 29(Suppl 4): S95-100. Go to original source...
    16. Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med 2012; 26(6): 501-507. Go to original source... Go to PubMed...
    17. Chiaravalloti A, Di Biagio D, Tavolozza M, Calabria F, Schillaci O. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤ 2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection? Eur J Nucl Med Mol Imaging 2016; 43(8): 1418-1424. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content